Novavax Statistics
NASDAQ: NVAXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
7.47-0.25 (-3.24%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Novavax by the numbers
Novavax has a market capitalization of $1.23 billion based on 165.01M shares outstanding. With trailing EPS of $-0.52, Novavax is unprofitable on a 12-month basis, so earnings-based valuation ratios do not apply. The stock trades 27.8% below its 50-day average and 19.8% below its 200-day average.
Average daily trading volume is 6.67M shares, or about $49.8 million in dollar volume.
Summary generated from market data by MetaCap's automated system. Methodology
NVAX valuation vs. peer median
| Metric | NVAX | Peer median | Difference |
|---|---|---|---|
| Market cap | $1.23B | $1.39B | -11% |
| Avg. volume | 6.67M | 698.28K | +855% |
Peer median across 8 companies: TSHA, VOR, IMCR, MESO, INBX, WWB, ALVO, RXRX.
Valuation
- Market cap
- $1.23B
- Price / sales (latest FY)
- 1.10
- EPS (TTM)
- $-0.52
- Shares outstanding
- 165.01M
Price and trading
- Previous close
- 7.72
- Open
- 7.59
- Day range
- 7.43 – 7.98
- 52-week range
- 6.36 – 13.39
- 52-week change
- +15.46%
- Beta
- —
- Volume
- 4.73M
- Average volume
- 6.67M
Dividends and events
- Annual dividend
- None
- Next earnings date
- Nov 5, 2026
Additional statistics
- Market Cap
- 1.23B
- Forward Pe
- -41.50
- Eps
- -0.52
- Dividend Yield
- 0.00%
- Dividend Rate
- 0.00
- Week52 High
- 13.39
- Week52 Low
- 6.36
- Avg Volume
- 6.67M
- Shares Outstanding
- 165.01M
- Ma50
- 10.34
- Ma200
- 9.32
- Earnings Date
- Nov 5, 2026
- Pct From52w High
- -44.21%
- Pct From52w Low
- 17.45%